Research Article

Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening

Table 3

Summary of designed peptides against SARS-CoV-2 peptides-MHC class I HLA-B interactions.

PeptideGlobal energy (kcal/Mol)Attractive VdW energy (kcal/Mol)H-Bond energy (kcal/Mol)Peptidase-MHC pairBond distance (Å)Conserved residues

GTDLEGNFY-43.24-28.870.22PHE8 O-ARG156 A
THR2 O-ILE66 CD1
THR2 N-ARG62 NH2
ASN7 OD1-TYR99 OH
TYR9 CZ-TRP147 CE2
SER4 CB-ILE66 CD1
2.020
2.474
2.575
1.319
2.194
2.315
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
TVNVLAWLY-50.38-32.3-3.03LEU8 C-TYR99 OH
LEU8 O-TYR99 OH
ALA6 O-ILE66 HG22
TRP7 CG-GLN70 CD
TYR9 O1-IL66 CG2
SER4 CB-ILE66 CD1
2.573
1.960
1.768
2.688
2.497
1.596
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
GSVGFNIDY-42.49-27.33-1.15PHE5 O-THR73 OG1
PHE5 O-THR73 CB
SER2 O-ILE66 CG2
ASP8 OD2-TYR99 CD1
ASN6 N-THR73 CG2
GLY4 CA-GLN70 OE1
0.425
1.321
2.103
2.144
2.559
2.698
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
QTFSVLACY-40.01-23.86-1.887TYR9 C-TYR116 OH
LEU6 O-ARG156 HD3
SER4 CB-ILE66 CD1
CYS8 CB-TYR99 OH
GLN1 OE1-ILE66 N
CYS8 O-TYR99 CD1
1.475
1.634
2.744
2.682
2.011
2.493
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
DYDCVSFCY-40.48-26.48-1.2CYS8 CB-GLN70 OE1
PHE7 CZ-ARG62 NH1
CYS8 SG-GLN70 OE1
ASP1 CG-GLU154 O
GLN1 OE1-ILE66 N
CYS8 O-TYR99 CD1
0.952
1.159
1.542
2.571
2.253
1.693
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
TANPKTPKY-32.96-23.45-1.65TYR9 C-THR73 OG1
LYS8 O-THR73 HG21
PRO7 CD-TRP147 CZ2
LYS5 CE-TYR99 OH
THR6 CA-TYR116 HH
1.336
0.712
2.509
2.317
2.027
2.693
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
SEDMLNPNY-29.63-26.6-0.72SER1 CB-THR73 OG1
LEU5 CD2-GLN70 OE1
MET4 CE-ILE66 CA
TYR9 O1-TYR159 HB2
0.732
1.252
2.377
1.283
1.986
2.563
TYR9
ARG62
ILE66
THR73
TYR99
GLU152
LLEDEFTPF-35.13-32.62-3.99PRO8 CB-THR73 OG1
LEU1 N-ARG156 CD
GLU5 O-ILE66 HG22
SER1 CB-THR73 OG1
LEU5 CD2-GLN70 OE1
MET4 CE-ILE66 CA
1.679
1.813
1.750
1.569
2.576
2.201
TYR9
ARG62
ILE66
THR73
TYR99
GLU152